Skip to main content
    V

    Voyager Therapeutics Inc (VYGR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.63
    -0.10 (-5.78%)

    Market Cap: $107.66M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Voyager Therapeutics Inc (VYGR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Voyager Therapeutics reported revenue of $40.37M for the fiscal year ended Dec 31, 2025, down 49.5% from the year before. That year, net income was -$119.72M with a net margin of -296.5%, operating cash flow was -$132.47M and free cash flow was -$135.06M. The quarter ended Sep 30, 2026 had revenue of $4.01M and net income of -$24.69M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $14.22M, a compound annual rate of 12.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$40.37M-49.5%100.0%-326.6%-296.5%
    Dec 2024$80.00M-68.0%100.0%-104.1%-81.3%
    Dec 2023$250.01M+511.2%100.0%48.8%52.9%
    Dec 2022$40.91M+9.3%100.0%-124.3%-113.4%
    Dec 2021$37.41M-78.1%100.0%-196.8%-190.3%
    Dec 2020$171.13M+63.9%100.0%16.0%21.5%
    Dec 2019$104.39M+1270.1%100.0%-49.5%-41.8%
    Dec 2018$7.62M-24.8%100.0%-1195.6%-1158.8%
    Dec 2017$10.13M-28.7%100.0%-709.1%-697.6%
    Dec 2016$14.22MN/A100.0%-290.4%-282.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$40.37M$80.00M$250.01M$40.91M$37.41M$171.13M$104.39M$7.62M$10.13M$14.22M
    Gross profit$40.37M$80.00M$250.01M$40.91M$37.41M$171.13M$104.39M$7.62M$10.13M$14.22M
    Research and development$134.67M$127.37M$92.17M$60.76M$73.79M$108.75M$119.73M$64.91M$62.26M$42.25M
    Operating income-$131.84M-$83.29M$122.01M-$50.84M-$73.62M$27.38M-$51.68M-$91.09M-$71.86M-$41.30M
    Net income-$119.72M-$65.00M$132.33M-$46.41M-$71.20M$36.74M-$43.60M-$88.29M-$70.70M-$40.19M
    EBITDA-$129.11MN/A$122.83M-$42.01M-$65.29M$38.93M-$50.87MN/A-$70.35M-$39.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$4.01M$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M$24.63M$29.58M$19.52M$90.06M
    Gross profit$4.01M$3.17M$2.59M$15.34M$13.37M$5.20M$6.47M$6.28M$24.63M$29.58M$19.52M$90.06M
    Operating income-$26.42M-$26.39M-$30.27M-$29.93M-$30.59M-$36.63M-$34.69M-$38.30M-$13.78M-$15.03M-$16.18M$54.06M
    Net income-$24.69M-$24.47M-$27.94M-$27.43M-$27.89M-$33.38M-$31.02M-$34.49M-$9.04M-$10.14M-$11.33M$56.40M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $7.84M by $57.46M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$252.28M$393.05M$351.28M$159.36M$193.85M$261.58M$354.76M$177.03M$184.48M$189.57M
    Current assets$202.69M$276.81M$319.68M$124.50M$136.70M$197.77M$304.66M$162.48M$171.79M$178.79M
    Cash and equivalents$65.30M$71.37M$68.80M$98.96M$117.43M$104.44M$86.04M$46.86M$31.53M$36.64M
    Total liabilities$56.20M$93.29M$114.96M$100.34M$98.80M$107.26M$255.25M$130.58M$50.43M$53.64M
    Short-term debt$7.84M$7.23M$3.20M$2.83M$5.57M$4.20M$3.19MN/AN/AN/A
    Shareholder equity$196.08M$299.76M$236.32M$59.02M$95.06M$154.32M$99.51M$46.45M$134.05M$135.92M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$177.05M$197.75M$219.32M$252.28M$288.31M$322.10M$353.24M$393.05M$426.04M$436.23M$469.59M$351.28M
    Total liabilities$41.94M$43.38M$45.66M$56.20M$68.49M$78.16M$80.54M$93.29M$95.73M$100.81M$128.71M$114.96M
    Cash and equivalents$48.41M$35.77M$43.31M$65.30M$45.13M$43.94M$74.75M$71.37M$112.53M$76.13M$143.08M$68.80M
    Shareholder equity$135.11M$154.38M$173.67M$196.08M$219.82M$243.94M$272.70M$299.76M$330.31M$335.42M$340.89M$236.32M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$132.47M-$15.31M$77.92M-$12.51M-$53.52M-$96.72M$48.67M-$15.89M-$61.35M-$42.48M
    Capital expenditures$2.60M$3.52M$3.26M$2.50M$1.61M$12.10M$7.72M$4.30M$3.98M$5.03M
    Free cash flow-$135.06M-$18.83M$74.66M-$15.01M-$55.13M-$108.81M$40.95M-$20.19M-$65.33M-$47.51M
    Investing cash flow$125.45M-$94.86M-$141.64M-$7.34M$65.91M$113.00M-$90.48M$26.47M-$3.68M$47.72M
    Financing cash flow$816.00K$114.02M$33.65M$1.11M$612.00K$3.16M$80.99M$4.75M$59.92M$514.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$19.67M-$25.84M-$33.42M-$30.26M-$31.05M-$33.26M-$37.90M-$14.53M-$27.97M-$31.58M$58.77M-$23.76M
    Capital expendituresN/AN/A$14.00K$626.00K$207.00K$1.10M$658.00K$155.00K$258.00K$967.00K$2.14M$755.00K
    Free cash flowN/AN/A-$33.43M-$30.89M-$31.25M-$34.37M-$38.55M-$14.68M-$28.23M-$32.55M$56.63M-$24.52M
    Last 12 quarters

    Frequently Asked Questions About VYGR

    What is Voyager Therapeutics' annual revenue?

    Voyager Therapeutics reported revenue of $40.37M for the fiscal year ended Dec 31, 2025.

    How fast is Voyager Therapeutics' revenue growing?

    Revenue was down 49.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.4%.

    Is Voyager Therapeutics profitable?

    No. Voyager Therapeutics reported net income of -$119.72M for the fiscal year ended Dec 31, 2025, with a net margin of -296.5%.

    How much free cash flow does VYGR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$132.47M minus capital expenditures of $2.60M produced free cash flow of -$135.06M.

    How much debt does Voyager Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $7.84M and cash and equivalents of $65.30M.